Nicola Ferrari, Translational Science Director of Immunology Cell Therapy at AstraZeneca, shared a post on LinkedIn:
“Pleased to share AstraZeneca’s 9M and Q3 results, demonstrating our strong growth momentum as we deliver for patients across the globe.
Total Revenue is up 11% and our pipeline is delivering with 16 positive Phase III trials this year.
Take a closer look below.”
More posts featuring AstraZeneca.
